EMA Recommends Extension of Therapeutic Indications for Selpercatinib
It adopted an extension of indication for the treatment of advanced RET-mutated medullary thyroid cancer
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1552 results
FDA Approves fam-Trastuzumab Deruxtecan-nxki for HER2-Low Breast Cancer
Evidence for efficacy is based on the results from the DESTINY-Breast04 study
TIL Densities Association with Disease-Free Survival Differs by Primary Tumour Sidedness in Stage III Colon Cancer
Findings from the NCCTG N0147 Alliance study analysis
Teclistamab Results in a High Rate of Deep and Durable Response in Patients with Triple-Class–Exposed Relapsed or Refractory Multiple Myeloma
Findings from the MajesTEC-1 study
EMA Recommends Granting a Conditional Marketing Authorisation for Teclistamab
It is indicated as monotherapy in adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies
Intratumoural Administration of the Oncolytic Herpes Virus Shows Survival Benefit and a Safe Profile in Patients with Residual or Recurrent Glioblastoma
Findings from a pivotal single-arm phase II study
Zero Mutation ctDNA Triage for Selection of Patients with Metastatic Colorectal Cancer for Panitumumab Rechallenge
Findings from the CHRONOS study
FDA Approves Darolutamide Tablets for Metastatic Hormone-Sensitive Prostate Cancer
Evidence for efficacy is based on the results from the ARASENS study
Marginal Benefit in Overall and Progression-Free Survival from New Anticancer Drugs
New anticancer drugs substantially reduce the risk of death and tumour progression, but only marginally extend patient survival
EMA Recommends Granting a Marketing Authorisation for Nivolumab / Relatlimab
It is indicated for the first-line treatment of advanced melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%
Neoadjuvant Niraparib Demonstrates Promising Antitumour Activity and Safety in Patients with Localised HER2-negative, BRCA-mutated Breast Cancer
Findings from the single-arm, phase II study
Trastuzumab Deruxtecan Shows High Intracranial Response Rate in Patients with Active Brain Metastases from HER2-positive Breast Cancer
Findings from the TUXEDO-1 study